Clinical

Adding metformin to the insulin regimen for pregnant patients with preexisting type 2 diabetes (T2D) or gestational diabetes diagnosed early in pregnancy did not reduce the risk of neonatal adverse outcomes.

Panelists provide final considerations surrounding biosimilar usage and considerations for optimal patient care.

Key topics for patient-provider conversations within the biosimilar landscape are highlighted by expert panelists.

Predicting clinical outcomes in patients with colorectal cancer (CRC) could be done using the novel comprehensive blood indicator PSI.

Experts address the need for lower costs of treatment, as well as ways payers can support patients with the use of biologics.

A medication monitoring program using medication bottles waws found to be effective in patients with sickle cell disease (SCD), though the usage will need additional support.

Among adults with type 2 diabetes who started noninsulin second-line therapy, most modified treatment within 1 year. Discontinuation was by far the most common modification.

Patients with B-cell malignancies who were intolerant to treatment with acalabrutinib experienced clinically meaningful benefits when treated with zanubrutinib, suggesting zanubrutinib may be a viable treatment option for this population.

Kevin Sheth, MD, discusses the role of computed tomography perfusion amid stroke diagnosis.

A trial comparing baricitinib against placebo in people with new-onset type 1 diabetes suggests use could contribute to the preservation of β-cell function.

A panel of medical experts discuss obstacles hindering the full potential of bispecifics.

Experts explore optimal conditions for effective bispecific therapy in an insightful panel discussion.

Patients receiving uncomplicated phacoemulsification surgery for cataracts had greater increases in macular and choroidal thickness if they had early diabetic retinopathy without preoperative diabetic macular edema.

Infants with HIV could be spared from requiring lifetime antiretroviral (ART) if treated within hours of birth to disrupt formation of HIV viral reservoirs.

Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology, discusses how dermatologists and clinicians can work towards increasing diversity and inclusion in treating patients with skin of color with plaque psoriasis.

Siamak Daneshmand, MD, provides closing remarks on the management of genitourinary cancers and the future of care.

An overview of the LITESPARK-003 study of belzutifan from ESMO 2023 and the role of HIF2α inhibitors in renal cell carcinoma (RCC).

Expert insight into the data presented at ESMO 2023 on the EV-302 study of enfortumab vedotin and pembrolizumab in the management of locally advanced or metastatic urothelial carcinoma.

Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.

Chronic obstructive pulmonary disease (COPD) is associated with fatal events in the long-term prognosis of stroke, but the association between COPD and short-term death in patients with stroke is insignificant.

Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort.

These new data highlight key points about the timeline of benefits for those who quit smoking cigarettes, including respiratory and cardiovascular benefits.

Although direct-mail self-sampling significantly increased cervical cancer screening, the opt-in approach only minimally increased screening.

Recent decades have seen marked improvements in hematological cancer outcomes and an expanded armamentarium of therapies, but novel treatments require updated strategies that are not always easy to fine-tune, according to presenters at the 2023 American Society of Hematology Annual Meeting and Exposition.

A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids.